• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Revolution Medicines (RVMD)

Common Shares
Sell: $100.00|Buy: $103.50|Change: 0.45 (-0.44%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

Address




Website

https://www.revmed.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Revolution Medicines Inc Fourth Quarter Earnings Conference Call for 20262027-02-25T16:30:00
Revolution Medicines Inc Fourth Quarter Earnings Results for 20262027-02-25T00:00:00
Revolution Medicines Inc Annual Report for 20262027-02-25T00:00:00
Revolution Medicines Inc Third Quarter Earnings Conference Call for 20262026-11-05T16:30:00
Revolution Medicines Inc Third Quarter Earnings Results for 20262026-11-05T00:00:00
Revolution Medicines Inc Second Quarter Earnings Conference Call for 20262026-08-06T16:30:00
Revolution Medicines Inc Second Quarter Earnings Results for 20262026-08-06T00:00:00
Revolution Medicines Inc Annual General Meeting for 20262026-06-26T07:30:00
Revolution Medicines Inc First Quarter Earnings Conference Call for 20262026-05-07T16:30:00
Revolution Medicines Inc First Quarter Earnings Results for 20262026-05-07T00:00:00
TD Cowen 46th Annual Health Care Conference2026-03-03T09:50:00

Previous key dates

NameKey Date
TD Cowen 46th Annual Health Care Conference2026-03-03T09:50:00
Revolution Medicines Inc Fourth Quarter Earnings Conference Call for 20252026-02-25T16:30:00
Revolution Medicines Inc Fourth Quarter Earnings Result for 20252026-02-25T00:00:00
Revolution Medicines Inc Annual Report for 20252026-02-25T00:00:00
Guggenheim Securities Emerging Outlook: Biotech Summit 2022026-02-11T09:30:00
44th Annual J.P. Morgan Healthcare Conference2026-01-12T10:30:00
Jefferies Global Healthcare Conference2025-11-18T09:30:00
Guggenheim 2 Annual Healthcare Innovation Conference2025-11-11T09:00:00
Revolution Medicines Inc Third Quarter Earnings Conference Call for 20252025-11-05T16:30:00
Revolution Medicines Inc Third Quarter Earnings Result for 20252025-11-05T00:00:00
Metastatic Pancreatic Cancer Update2025-09-10T17:00:00
Revolution Medicines Inc Second Quarter Earnings Conference Call for 20252025-08-06T16:30:00
Revolution Medicines Inc Second Quarter Earnings Results for 20252025-08-06T00:00:00
Revolution Medicines Inc Annual General Meeting for 20252025-06-26T07:30:00
Revolution Medicines Inc First Quarter Earnings Conference Call for 20252025-05-07T16:30:00
Revolution Medicines Inc First Quarter Earnings Result for 20252025-05-07T00:00:00
Stifel 2025 Virtual Targeted Oncology Forum2025-04-09T13:00:00
Needham 24th Annual Virtual Healthcare Conference2025-04-07T14:15:00
2025 Leerink Partners Global Healthcare Conference2025-03-12T14:20:00
Barclays 27th Annual Global Healthcare Conference2025-03-11T08:00:00
TD Cowen 45th Annual Healthcare Conference2025-03-03T13:50:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.